Ciclesonide nasal spray: in allergic rhinitis

Area of Science:

• Pharmacology
• Allergology
• Respiratory Medicine

Background:

• Corticosteroids are a mainstay in allergic rhinitis treatment.
• Ciclesonide is a novel inhaled corticosteroid with a unique delivery mechanism.
• Intranasal administration aims for localized effects with minimal systemic absorption.

Purpose of the Study:

• To evaluate the efficacy and safety of ciclesonide nasal spray in patients with seasonal and perennial allergic rhinitis.
• To assess the impact of ciclesonide on nasal symptoms and quality of life.

Main Methods:

• Randomized, placebo-controlled trials were conducted in adolescent and adult populations.
• Ciclesonide nasal spray (200 microg once daily) was administered for durations of 2-4 weeks (seasonal) and 6 weeks/1 year (perennial).
• Nasal symptom scores and quality of life measures were primary endpoints.

Main Results:

• Ciclesonide nasal spray significantly improved nasal symptoms compared to placebo in both seasonal and perennial allergic rhinitis.
• Quality of life improvements were noted in the initial 2 weeks for seasonal allergic rhinitis but not considered clinically relevant for perennial allergic rhinitis.
• The drug was generally well-tolerated, with most adverse events being mild to moderate.

Conclusions:

• Intranasal ciclesonide is an effective treatment for moderate to severe allergic rhinitis in adolescents and adults.
• The medication exhibits a favorable safety profile with low systemic exposure.
• Ciclesonide nasal spray offers a viable therapeutic option for managing allergic rhinitis symptoms.